Pyramid Analytics Named CRN Channel Awards 2022 Finalist
15.9.2022 10:00:00 EEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, is a CRN Channel Awards 2022 finalist in the Emerging Vendor of the Year category. The Emerging Vendor of the Year category recognises new and emerging organisations which have successfully supported the growth of their channel partners in the UK. CRN reported a record number of award entries. Expanding channel partnerships with complementary technology companies, independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI) is a strategic priority. Pyramid has expanded its Alliances team and partner recruitment capabilities, invested in partner training and development, and launched joint go to market programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005045/en/
Bill Clayton, Vice President, Global Alliances for Pyramid Analytics (Photo: Business Wire)
Key Points:
- Pyramid Analytics is a finalist in the Emerging Vendor of the Year category of the CRN Channel Awards 2022.
- The channel partner programme is the backbone of Pyramid’s UK operations, accounting for a significant segment of UK revenue.
- Pyramid partners in the UK include Amplifi, AND Grow International Ltd, Ascot London Consulting Limited, AWS, Delaware, Snap Analytics.
- The winners of the CRN Channel Awards 2022 will be announced at an award ceremony on November 10 at Evolution London in the heart of London’s iconic Battersea Park.
- To learn more about becoming a Pyramid partner in the UK & Ireland, contact bill.clayton@pyramidanalytics.com.
Pyramid Analytics Demonstrates its Commitment to and Value for Channel Partners
The CRN Channel Awards is one of the highest accolades in the UK channel. It recognises excellence across the UK channel landscape, with categories covering Vendors, Distributors and Resellers. All entries face a rigorous judging process from industry leaders. The judges this year recognised the particularly “strong competition” with several of the categories receiving a record number of entries.
Being shortlisted for the award is a culmination of Pyramid’s four and a half years of commitment to the UK economy, with the growth of its channel partnerships at the core of its business strategy and success. 2022 has been the most momentous year for Pyramid in the UK with the hiring of Tom Warren as Managing Director for UKI and the announcement of a $120 million Series E funding round announcement at a special event at Tower Bridge.
Channel partners are critical for Pyramid’s ability to continue to grow in a scalable manner, in turn offering them access to pioneering innovative technology that can transform their business. Pyramid understands that for outstanding growth to be achieved for the company and for its channel partners, its partners should be thoroughly supported with training to develop in-depth knowledge and insights. Pyramid’s partner portal is vital in delivering learning, development and growth value for Pyramid and its partners.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Tom Warren , Vice President of UKI, Pyramid Analytics: “The entire Pyramid team is delighted and proud to have been shortlisted for the CRN Channel Awards. To be shortlisted as an Emerging Vendor of the Year really is the icing on the cake for what has been a brilliant year for the company and for our channel partners. The fact the Series E funding round was announced in the UK was a strong signal of our intent and commitment to the UK – and we’re only getting started. I would like to take this opportunity to say a massive thank you to CRN for this recognition, to the Pyramid team and our amazing channel partners who believe in us and stand by us.”
Bill Clayton , Vice President of Global Partner Sales, Pyramid Analytics: “The CRN Channel Awards are closely watched by everyone in the UK channel ecosystem, and it’s a momentous occasion for the whole Pyramid family to be nominated. For Pyramid, our channel partnerships have become an essential cornerstone of our business. Our highly productive and effective work with channel partners has forged a host of mutually beneficial relationships that have driven growth for all involved across the UK. Channel partners are now the core of Pyramid’s business. The upcoming growth and expansion of the company is firmly embedded with our channel partners, and I look forward to making that future a reality.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005045/en/
Contact information
UK
Alex Izza
Resonance
07591899654
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
